- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03333720
Compliance, Tolerance and Acceptability of a Tablet Protein Substitute for the Dietary Management of Phenylketonuria
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Protein substitutes are typically presented in powder format and reconstituted in water to a set volume, but may also be offered in ready-to-drink formats or as a gel. Notwithstanding recent advancements related to the taste, scent and texture (organoleptic properties) of commercially available protein substitutes, a small proportion of PKU patients choose to consume tablet-based protein substitutes. In this sense, anecdotal evidence suggests that in the UK approximately 80-100 PKU patients consume tablet protein substitutes. Despite the need to consume large quantities, protein substitutes in tablet format may help overcome some of the aforementioned limitations compared to powdered or ready-to-drink preparations, but also offer additional benefits including convenience and reduced preparation.
Although usage of tablet-based protein substitutes is low in comparison to powdered preparations, early evidence from MacDonald and colleagues suggests tablet protein substitutes are an equally effective strategy to manage PKU in older children, teenagers and adults. Tablet-based protein substitutes, however, only offer a balanced mixture of essential and non-essential amino acids. Considering the daily burden and discipline required to follow the restrictive low-protein diet, reports suggest achieving full compliance with tablet-based protein substitutes is difficult, and this becomes especially challenging when given alongside multi vitamin supplements. To elaborate, patients solely consuming protein substitutes in tablet format may be required to consume 70-140 tablets per day (average = 75 tablets per day) alongside an additional 5 prescribable vitamin and mineral tablets. In this instance, it may be beneficial if tablet-based protein substitutes combined amino acids with vitamins, minerals and trace elements.
At present, tablets combining amino acids with vitamins, minerals and trace elements are currently unavailable. As such, the sponsor has produced a tablet-based protein substitute designed for individuals aged 8 years and older. Developed specifically for the dietary management of proven PKU, the phenylalanine-free protein substitute tablets comprise an adapted mixture of essential and non-essential amino acids (excluding phenylalanine) and are combined with carbohydrates, DHA, vitamins and selected minerals and trace elements. As such, the aim of this intervention trial is therefore to evaluate the acceptability (compliance, gastrointestinal tolerance and palatability) of the tablets, while also capturing information related to blood amino acid profiles, dietary intake, anthropometry and safety as part of a low phenylalanine dietary regimen in PKU patients. Thirty eligible PKU patients (≥ 8 years), identified as current tablet users, will be recruited. Patients will firstly observe a 7-day baseline period. During baseline, patients will continue with their existing diet and protein substitute prescription before receiving the tablets daily for 28 days in addition to appropriate nutritional management.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female
- 8 years of age and older
- Diagnosed with proven PKU
- Consume a minimum of 20g protein equivalent in tablet format while enrolled on to the trial
- If routine care and dietary management is not different from normal PKU care and dietary management, preconception patients may be considered
- Have written informed consent from patient or parent/carer carer
Exclusion Criteria:
- Requiring nutritional support (including enteral and parenteral nutrition)
- Major hepatic or renal dysfunction
- Maternal PKU patients (if a patient becomes pregnant during the study they will be withdrawn on immediate notice to the Metabolic Dietitian responsible for the patient's care)
- Participation in other studies within 1 month prior to entry of this study
- Investigator concern around willingness/ability of patient to comply with protocol requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Intervention is phenylalanine-free protein substitute.
Following a 7 day baseline period, all recruits will receive the new phenylalanine-free protein substitute daily for 28 days in addition to routine nutritional management.
The study product prescription will be specified on an individual basis by the metabolic Dietitian responsible for the patient's nutritional management and will be dependent on age, bodyweight and medical condition of the patient, but will wholly replace their currently prescribed tablet protein substitute and multivitamin supplements.
|
Thirty eligible PKU patients (≥ 8 years), identified as current tablet users, will be recruited to this study.
Patients will firstly observe a 7-day baseline period.
During baseline, patients will continue with their existing diet and protein substitute prescription before receiving Phenylalanine-free protein subsitute tablets daily for 28 days in addition to appropriate nutritional management.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daily Compliance
Time Frame: 35 days
|
Compliance with currently prescribed protein substitute and prescribed multivitamin supplements will be assessed daily from days 1-7 and recorded as a percentage of tablets consumed comapred to prescription (0-100%).
Compliance with the study product will subsequently be assessed daily from days 8-35.
Compliance throughout the trial will be assessed using standarised questionnaires, where patients document number of med versus number of tablets prescribed.
A percentage compliance level based on per patient and total patients will be computed to define overall compliance where a higher percentage represents better overall compliance.
|
35 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-Emergent tolerability
Time Frame: 12 days
|
Gastrointestinal tolerance (including diarrhoea, constipation, nausea, vomiting, abdominal pain, bloating, flatulence and burping) will be assessed via questionnaire using the scale (absent, mild, moderate, severe).
|
12 days
|
Patient Acceptability
Time Frame: 2 days
|
Acceptability (ease of use and palatability) will be assessed via questionnaire.
|
2 days
|
Metabolic control
Time Frame: 2 days
|
Blood phenylalanine, blood tyrosine and other amino acids.
Fingertip-capillary blood samples will be collected in the fasted state at baseline observations (day 1), and on the last day of the intervention period (day 35).
Collected samples will be analysed for blood phenylalanine, tyrosine and 16 other proteinogenic amino acids, 2 non-proteinogenic amino acids and 1 amino sulfonic acid.
|
2 days
|
Nutritional Intake
Time Frame: 2 days
|
To assess habitual dietary intake, 24 hour dietary recalls will be completed during baseline and at the end of the intervention period.
|
2 days
|
Weight
Time Frame: 2 days
|
Measures of weight (kg) will be made during baseline observations and at the end of the intervention period.
|
2 days
|
Height
Time Frame: 2 days
|
Measures of weight (kg) will be made during baseline observations and at the end of the intervention period.
|
2 days
|
Incidence of study product emergent adverse events [safety].
Time Frame: Baseline
|
All adverse events will be recorded throughout the study (as and when they occur).
Consequently, there is no specific time frame as the frequency of adverse events can not be predicted.
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Rebecca Stratton, PhD, Nutricia, Inc.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PKU.LP2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phenylketonurias
-
Lumos DiagnosticsAptatek BiosciencesRecruiting
-
SanofiRecruiting
-
Children's Hospital of Fudan UniversityHedu Biotechnology (Shanghai) Co., LTDRecruiting
-
University Hospital, GrenobleRecruitingMetabolic Diseases | PhenylketonuriaFrance
-
APR Applied Pharma Research s.a.Recruiting
-
University Children's Hospital, ZurichUniversity Children's Hospital Basel; UChildrenVienna; Insel Gruppe AG, University...RecruitingPhenylketonuriasSwitzerland
-
University Hospital, LilleNot yet recruiting
-
Emory UniversityBioMarin PharmaceuticalRecruitingPhenylketonuriasUnited States
-
Vitaflo International, LtdCompleted
-
Vitaflo International, LtdJohannes Gutenberg University Mainz; Kreiskliniken ReutlingenCompleted
Clinical Trials on Phenylalanine-free protein substitute tablets
-
metaX Institut fuer Diatetik GmbHBirmingham Children's HospitalCompletedPhenylketonurias | Hyperphenylalaninaemia | Tetrahydrobiopterin DeficiencyUnited Kingdom
-
Nutricia UK LtdCompletedPKU | TyrosinemiasUnited Kingdom
-
Nutricia UK LtdNot yet recruitingPhenylketonurias | Hyperphenylalaninaemia
-
University Medical Centre LjubljanaNot yet recruitingPhenylketonurias | Nutritional and Metabolic Diseases
-
Vitaflo International, LtdArla FoodsCompletedPhenylketonuriasUnited Kingdom, Denmark
-
Chang Gung Memorial HospitalRecruitingNon-Phenylketonuric HyperphenylalaninemiaTaiwan
-
Nutricia ResearchCompleted
-
Teva Pharmaceuticals USACompleted
-
University of Illinois at Urbana-ChampaignCompleted